SEARCH

SEARCH BY CITATION

References

  • Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366375.
  • Andersson M., Hilbertson A. and Cenci M. A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461474.
  • Andersson M., Konradi C. and Cenci M. A. (2001) CREB is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J. Neurosci. 21, 99309943.
  • Bezard E., Ravenscroft P., Gross C. E., Crossman A. R. and Brotchie J. M. (2001) Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Neurobiol. Dis. 8, 343350.
  • Brotchie J. M., Henry B., Hille C. J. and Crossman A. R. (1998) Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease, in Advances in Neurology, Dystonia 3 (Fahn S., Marsden C. D. and DeLong M. R., eds), Vol. 78, pp. 4152. Lippincott-Raven Publishers, Philadelphia, PA, USA.
  • Carta A. R., Pinna A., Cauli O. and Morelli M. (2002) Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A(2A) receptor blockade plus l-Dopa in dopamine-denervated rats. Synapse 44, 166174.
  • Cenci M. A., Lee C. S. and Bjorklund A. (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 26942706.
  • Cenci M. A., Tranberg A., Andersson M. and Hilbertson A. (1999) Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-DOPA treatment. Neuroscience 94, 515527.
  • Cenci M. A., Whishaw I. Q. and Schallert T. (2002) Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neuroscience 3, 574579.
  • Chen J. F., Xu K., Petzer J. P., Staal R., Xu Y. H., Beilstein M., Sonsalla P. K., Castagnoli K., Castagnoli N. Jr and Schwarzschild M. A. (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143.
  • Doucet J.-P., Nakabeppu Y., Bedard P. J. et al. (1996) Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of delta-FosB-like proteins in both the rodent and primate striatum. Eur. J. Neurosci. 8, 365381.
  • Fenu S., Pinna A., Ongini E. and Morelli M. (1997) Adenosine A2A receptor antagonism potentiates l-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321, 143147.
  • Fredduzzi S., Moratalla R., Monopoli A., Cuellar B., Xu K., Ongini E., Impagnatiello F., Schwarzschild M. A. and Chen J. F. (2002) Persistent behavioral sensitization to chronic l-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 10541062.
  • Fuxe K., Ferre S., Zoli M. and Agnati L. F. (1998) Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Rev. 26, 258273.
  • Fuxe K., Stromberg I., Popoli P., Rimondini-Giorgini R., Torvinen M., Ogren S. O., Franco R., Agnati L. F. and Ferre S. (2001) Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv. Neurol. 86, 345353.
  • Ikeda K., Kurokawa M., Aoyama S. and Kuwana Y. (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80, 262270.
  • Jenner P. (2000) Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J. Neurol. 247, II43-50.
  • Johansson P. A., Andersson M., Andersson K. E. and Cenci M. A. (2001) Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol. Dis. 8, 220239.
  • Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y. and Jenner P. (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507513.
  • Kanda T., Jackson M. J., Smith L. A., Pearce R. K., Nakamura J., Kase H., Kuwana Y. and Jenner P. (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol. 162, 321327.
  • Kincaid A. and Wilson C. J. (1996) Corticostriatal innervation of the patch and matrix in the rat neostriatum. J. Comp. Neurol. 374, 578592.
  • Koga K., Kurokawa M., Ochi M., Nakamura J. and Kuwana Y. (2000) Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur. J. Pharmacol. 408, 249255.
  • Kurokawa M., Koga K., Kase H., Nakamura J. and Kuwana Y. (1996) Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66, 18821888.
  • Lee C. S., Cenci M. A., Schulzer M. and Bjorklund A. (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 123, 13651379.
  • Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci M. A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120132.
  • McGeorge A. J. and Faull R. L. M. (1989) The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29, 503537.
  • Mori A., Shindou T., Ichimura M., Nonaka H. and Kase H. (1996) The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16, 605611.
  • Mouradian M. M., Heuser I. J. E., Baronti F., Fabbrini G., Juncos J. L. and Chase T. N. (1989) Pathogenesis of dyskinesias in Parkinson's disease. Ann. Neurol. 25, 523526.
  • Obeso J. A., Olanow C. W. and Nutt J. G. (2000) Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2S7.
  • Paxinos G. and Watson C. (1997) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA, USA.
  • Pinna A., Fenu S. and Morelli M. (2001) Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39, 233238.
  • Richardson P. J., Kase H. and Jenner P. G. (1997) Adenosine A2a receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 18, 338344.
  • Rozas G. and Labandeira Garcia J. L. (1997) Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test. Brain Res. 749, 188199.
  • Rozas G., Guerra M. J. and Labandeira-Garcia J. L. (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Protoc. 2, 7584.
  • Schmidt R. H., Ingvar M., Lindvall O., Stenevi U. and Björklund A. (1982) Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C] 2-deoxy-d-glucose autoradiography. J. Neurochem. 38, 737748.
  • Schneider J. S., Decamp E. and Wade T. (1999) Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J. Neurosci. 19, 66436649.
  • Schwarting R. K. W. and Huston J. P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275331.
  • Svenningsson P., Le Moine C., Fisone G. and Fredholm B. B. (1999) Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355396.
  • Westin J. E., Andersson M., Lundblad M. and Cenci M. A. (2001) Persistent changes in striatal gene expression induced by long-term l- DOPA treatment in a rat model of Parkinson's disease. Eur. J. Neurosci. 14, 11711176.
  • Winkler C., Kirik D., Björklund A. and Cenci M. A. (2002) l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165186.
  • Zeng B. Y., Pearce R. K., MacKenzie G. M. and Jenner P. (2000) Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with l-DOPA. Eur. J. Neurosci. 12, 10961104.